Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 2:16:575-595.
doi: 10.2147/DMSO.S387116. eCollection 2023.

The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials

Malikah Aldawsari #  1 , Fatima A Almadani #  1 , Nujud Almuhammadi  1 , Sarah Algabsani  1 , Yara Alamro  1 , Madhawi Aldhwayan  1
Affiliations
Review

The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials

Malikah Aldawsari et al. Diabetes Metab Syndr Obes. .

Abstract

Background: Obesity is an epidemiological issue that negatively affects public health and has led to a high global burden on the healthcare system. Several approaches to control and overcome the obesity crisis have been established. However, Nobel discoverers found that glucagon-like peptide-1 analogues (GLP-1 analogues) positively regulate appetite and food intake, eventually leading to weight loss.

Objective: The present systematic review aims to summarize the currently available evidence of the impact of GLP-1 analogues on appetite, gastric emptying, taste sensitivity, and food preferences among adults with obesity without other chronic diseases.

Methods: A systematic literature search was conducted from October 2021 to December 2021 from three electronic databases (PubMed, Scopus, and ScienceDirect), including only randomized clinical trials (RCTs). Studies were based on the use of GLP-1 analogues, of any dosage and duration among adults with obesity without other medical diseases; studies measured appetite, gastric emptying, food preferences, and taste as a primary or secondary outcome. The risk of publication bias in each study was assessed independently using the updated Cochrane risk-of-bias tool (RoB2).

Results: Twelve studies met the inclusion criteria with a total sample size of 445 participants. All the included studies measured at least one or more of the primary outcomes. The promising effect was evidenced by most studies showing appetite suppression, delayed gastric emptying, and changes in taste and food preferences.

Conclusion: GLP-1 analogues are effective obesity management therapy that could decrease food intake and eventually reduce weight by suppressing appetite, reducing hunger, decreasing gastric emptying, and altering food preferences and taste. However, high-quality, long-term, large sample size studies are crucial to examine the efficacy and effective dose of GLP-1 analogues intervention.

Keywords: GLP-1 analogues; Liraglutide; Semaglutide; appetite; gastric emptying; palatability; satiety.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA flow diagram for the study.
Figure 2
Figure 2
Summary of risk of bias for all included studies.
Figure 3
Figure 3
Risk of bias graph for all included studies.
See this image and copyright information in PMC

References

    1. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1–203. doi:10.4158/EP161365.GL - DOI - PubMed
    1. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424. doi:10.1159/000442721 - DOI - PMC - PubMed
    1. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384(9945):766–781. doi:10.1016/S0140-6736(14)60460-8 - DOI - PMC - PubMed
    1. Althumiri NA, Basyouni MH, Almousa N, et al. Obesity in Saudi Arabia in 2020: prevalence, distribution, and its current association with various health conditions. Healthc. 2021;9(3):1–8. doi:10.3390/healthcare9030311 - DOI - PMC - PubMed
    1. Kushner RF. Weight loss strategies for treatment of obesity. Prog Cardiovasc Dis. 2014;56(4):465–472. doi:10.1016/j.pcad.2013.09.005 - DOI - PubMed